SARS-CoV-2 (Covid-19) Inhibitor Screening ELISA


The SARS-CoV-2 Covid-19 Inhibitor Screening ELISA Assay kit is used for inhibitor screening of Covid-19 in biological samples and human serum. The SARS-CoV-2 Covid-19 Inhibitor Screening ELISA Assay kit is for research use only and not to be used for diagnostic procedures.

SARS-CoV-2 (Covid-19) Inhibitor Screening ELISA

The SARS-CoV-2 Covid-19 Inhibitor Screening ELISA Assay is For Research Use Only

Size: 12×8 wells
Sensitivity: 15.63 pg/ml
Standard Range: 0 pg/ml – 10 pg/ml
Incubation Time: 2 hours 15 minutes
Sample Type: Serum and Plasma
Sample Size: 100 μl

SARS-CoV-2 (Covid-19) Inhibitor Screening ELISA Assay Principle

The SARS-CoV-2 ELISA Assay employs sandwich ELISA technique. Human SARS-CoV-2 S protein RBD is pre-coated onto microwells. Human ACE2 and Inhibitor in the Samples compete and Inhibitor Control are pipetted into microwells. The Inhibitor in the Samples and Control will inhibit the ACE2 from binding to the SARS-CoV-2 s protein RBD to form a complex. After incubation the wells are washed and HRP-conjugated Detection antibody is pipetted and incubated to form a complex. After washing microwells in order to remove any non-specific binding, the substrate solution (TMB) is added to microwells and color develops in inverse proportional to the amount of Inhibitor. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Sample Preparation and Storage for the SARS-CoV-2 ELISA

Preparation and Storage:

  • Specimens should be clear and non-hemolyzed. Samples should be run at a number of dilutions to ensure accurate quantitation.
  • Blood is taken by venipuncture. Serum is separated after clotting by centrifugation. Plasma can be used, too. Lipaemic, hemolytic or contaminated samples should not be run. Repeated freezing and thawing should be avoided. If they are to be used for several SARS-CoV-2 assays, initially aliquot samples and keep at – 20°C

Preparation before Use:

  • Allow serum samples to reach room temperature prior to SARS-CoV-2 assay. Take care to agitate patient samples gently in order to ensure homogeneity.
  • Samples should be diluted 1:5000 (v/v) for optimal recovery, (for example 1 µl sample + 4999 µl sample diluent) prior to SARS-CoV-2 assay. In cases where matrix interferences is under or over observed, they may be diluted with Sample Diluent accordingly.
  • The samples may be kept at 2 – 8°C for up to three days. For long-term storage please store at -20°C.

Note: Grossly hemolyzed samples are not suitable for use in this SARS-CoV-2 ELISA assay.

  • Biological Samples: Dilute each SARS-CoV-2 inhibitor (chemicals or antibodies) to be tested to the desired final concentration in 100 ul of SARS-CoV-2 Assay Diluent.

Note: Do not exceed 0.1% DMSO if using chemicals as inhibitors

Related Products to SARS-CoV-2 Inhibitor Screening ELISA Assay:

SARS-CoV-2 (2019-nCoV) Spike RBD Antigen Quantitative ELISA Assay Kit

SARS-CoV-2 (Covid-19) (Wild Type + South African Variant) RBD Antigen Quantitative ELISA Assay Kit

COVID19S-REAAD Anti-SARS-CoV-2 Total Antibodies ELISA Assay Kit

Additional Information

Assay Background

The SARS CoV-2 (Covid-19) Inhibitor Screening ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a sandwich ELISA technique which leads to a higher specificity and increased sensitivity compared to conventional competitive ELISA kits which employ only one antibody. Double antibodies are used in this kit.

The SARS-CoV-2 comprises 4 structural proteins – Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.

The SARS-CoV-2 Inhibitor Screening ELISA measures the binding of the RBD of the Spike S protein from SARS-CoV-2 to its human receptor ACE2. Thus, this assay allows to identify and characterize the effect of different inhibitory molecules including antibodies or chemicals on the inhibition of the binding of SARS-CoV-2 virus to any ACE2-expressing cells.

Package Inserts

Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Product Citations